U.S. patent number 3,875,011 [Application Number 05/438,890] was granted by the patent office on 1975-04-01 for enzyme immunoassays with glucose-6-phosphate dehydrogenase.
This patent grant is currently assigned to Syva Company. Invention is credited to Kenneth Edward Rubenstein, Edwin F. Ullman.
United States Patent |
3,875,011 |
Rubenstein , et al. |
April 1, 1975 |
**Please see images for:
( Certificate of Correction ) ** |
Enzyme immunoassays with glucose-6-phosphate dehydrogenase
Abstract
Novel conjugated enzyme compositions are provided for use in
homogeneous enzyme immunoassays. A wide variety of haptenic
compounds, particularly drugs of abuse, and drugs used in
repetitive therapeutic applications, and steroids are conjugated to
glucose-6-phosphate dehydrogenase. The resulting product has a
higher turnover rate, so as to provide a high multiplication factor
when employed in a homogeneous enzyme immunoassay.
Inventors: |
Rubenstein; Kenneth Edward
(Palo Alto, CA), Ullman; Edwin F. (Atherton, CA) |
Assignee: |
Syva Company (Palo Alto,
CA)
|
Family
ID: |
26973837 |
Appl.
No.: |
05/438,890 |
Filed: |
February 1, 1974 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
304157 |
Nov 6, 1972 |
|
|
|
|
143609 |
May 14, 1971 |
|
|
|
|
Current U.S.
Class: |
435/188; 435/7.9;
435/964; 435/26 |
Current CPC
Class: |
G01N
33/946 (20130101); G01N 33/948 (20130101); G01N
33/9486 (20130101); G01N 33/535 (20130101); Y10S
435/964 (20130101) |
Current International
Class: |
G01N
33/94 (20060101); G01N 33/535 (20060101); C07g
007/02 () |
Field of
Search: |
;195/63,99,13.5R,DIG.11 |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
3791932 |
February 1974 |
Schuurs et al. |
|
Primary Examiner: Tanenholtz; Alvin E.
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No.
304,157, filed Nov. 6, 1972, which is in turn a
continuation-in-part of application Ser. No. 143,609, filed May 14,
1971, now abandoned.
Claims
What is claimed is:
1. An enzyme conjugate of glucose-6-phosphate dehydrogenase of the
formula:
G--6--PDH } (X--R--Y).sub.n
wherein:
G--6--pdh intends glucose-6-phosphate dehydrogenase;
n is the average number of groups bonded to the G--6--PDH and is in
the range of 1 to 18;
X is a bond or non-oxocarbonyl, including the nitrogen and sulfur
analogs thereof;
R is an aliphatic linking group of from 1 to 8 carbon atoms and 0
to 3 heteroatoms which are oxygen, sulfur, or nitrogen;
Y is a hapten of at least 125 molecular weight and not greater than
about 1,000 molecular weight.
2. An enzyme conjugate according to claim 1, wherein n is of from 2
to 12, X is a non-oxocarbonyl group, R is of from 1 to 4 carbon
atoms and 0 to 2 heteroatoms, and Y is a hapten of from about 125
to about 650 molecular weight.
3. An enzyme conjugate according to claim 1 wherein said
glucose-6-phosphate dehydrogenase is derived from the bacterium
L.mesenteroides.
4. An enzyme conjugate of the formula: ##SPC10##
wherein:
T is hydrogen or acetyl;
n.sup.1 is on the average 1 to 14;
X.sup.1 is a bond, non-oxocarbonyl, including the thio and nitrogen
analogs thereof or, when R.sup.1 is aromatic hydrocarbon, diazo;
and
R.sup.1 is an aliphatic group of from 1 to 8 carbon atoms and 0 to
3 heteroatoms which are oxygen, sulfur or nitrogen or aromatic
hydrocarbon of from 6 to 9 carbon atoms.
5. An enzyme conjugate according to claim 4, wherein X.sup.1 is
non-oxocarbonyl, R.sup.1 is a saturated aliphatic group of from 1
to 4 carbon atoms and T is hydrogen.
6. An enzyme conjugate of the formula: ##SPC11##
wherein:
n.sup.2 is on the average from 1 to 14;
T.sup.1 and T.sup.2 are hydrocarbon of from 1 to 7 carbon atoms
having from 0 to 1 sites of aliphatic unsaturation;
one of W and W.sup.1 is -R.sup.2 -X.sup.2 - and the other is
hydrogen;
m is 0 or 1, with the proviso that when m is 0, T.sup.1 and T.sup.2
are phenyl;
Z is oxygen with the proviso that Z may be H.sub.2 when one of
T.sup.1 and T.sup.2 is phenyl and m is 1;
X.sup.2 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof or, when R.sup.2 is aromatic hydrocarbon,
diazo; and
R.sup.2 is an aliphatic group of from 1 to 8 carbon atoms and from
0 to 3 heteroatoms which are oxygen, sulfur or nitrogen, or
aromatic hydrocarbon of from 6 to 9 carbon atoms.
7. An enzyme conjugate according to claim 6, wherein m is 0, Z is
oxygen, and R.sup.2 is of from 1 to 4 carbon atoms and from 0 to 2
heteroatoms.
8. An enzyme conjugate according to claim 6, wherein m is 1, Z is
oxygen, R.sup.2 is of from 1 to 4 carbon atoms and from 0 to 2
heteroatoms and X.sup.2 is non-oxocarbonyl.
9. An enzyme conjugate according to claim 8, wherein X.sup.2 is the
oxygen moiety.
10. An enzyme conjugate according to claim 8, wherein X.sup.2 is
the nitrogen moiety.
11. An enzyme conjugate of the formula: ##SPC12##
wherein:
n.sup.3 is on the average in the range of 1 to 14;
one of Z.sup.1, Z.sup.2 and Z.sup.3 is --R.sup.3 --X.sup.3 --,
wherein R.sup.3 may be singly or doubly bonded to the annular
carbon atom, and R.sup.3 is an aliphatic group of from 1 to 8
carbon atoms and 0 to 3 heteroatoms, which are oxygen, sulfur or
nitrogen, or aromatic hydrocarbon of from 6 to 9 carbon atoms;
when other than --R.sup.3 --X.sup.3 --, Z.sup.2 and Z.sup.3 are
hydrogen;
X.sup.3 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof or, when R.sup.3 is aromatic hydrocarbon,
diazo;
with the proviso that when the steroid is a gestogen, there is from
0 to 1 site of ethylenic unsaturation in the .DELTA..sup.4 or
.DELTA..sup.5 position; and
when other than --R.sup.3 --X.sup.3 --, Z.sup.1 is hydroxyl or
oxo;
Y.sup.1 is acetyl; and
Y.sup.2 and Y.sup.3 are hydrogen;
when the steroid is an androgen, when other than--R.sup.3 --X.sup.3
--,
Z.sup.1 is oxo;
Y.sup.1 is hydroxyl; and
Y.sup.2 and Y.sup.3 are hydrogen; and
when the steroid is an adrenocortical hormone, when other than
--R.sup.3 --X.sup.3 --, Z.sup.1 is oxo;
Y.sup.1 is hydroxyacetyl;
Y.sup.2 is hydrogen or hydroxyl; and
Y.sup.3 is hydroxy or oxo.
12. An enzyme conjugate of the formula: ##SPC13##
wherein:
one of Z.sup.4, Z.sup.5 and Z.sup.6 is --R.sup.4 --X.sup.4 --,
wherein when Z.sup.4 or Z.sup.6 is --R.sup.4 --X.sup.4 --, R.sup.4
may be singly or doubly bonded to the annular carbon atom and
wherein R.sup.4 is an aliphatic radical of from 1 to 8 carbon
atoms, and from 0 to 3 heteroatoms which are oxygen, nitrogen and
sulfur or aromatic hydrocarbon of from 6 to 9 carbon atoms;
X.sup.4 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof or, when R.sup.4 is aromatic hydrocarbon,
diazo;
when other than --R.sup.4 --X.sup.4 --, Z.sup.4, Z.sup.5 and
Z.sup.6 are hydrogen;
Y.sup.4 is hydrogen or hydroxyl; and
n.sup.4 is on the average in the range of from 1 to 14.
13. An enzyme conjugate of the formula: ##SPC14##
wherein:
R.sup.5 is an aliphatic radical of from 1 to 8 carbon atoms and
from 0 to 3 heteroatoms which are oxygen, sulfur or nitrogen or
aromatic hydrocarbon of from 6 to 9 carbon atoms;
X.sup.5 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof or, when R.sup.5 is aromatic hydrocarbon,
diazo; and
n.sup.5 is on the average in the range of from 1 to 14.
14. An enzyme conjugate of the formula: ##SPC15##
wherein:
one of Z.sup.7, Z.sup.8 and Z.sup.9 is R.sup.6 --X.sup.6, wherein
when Z.sup.8 or Z.sup.9 is R.sup.6 --X.sup.6, R.sup.6 may be singly
or doubly bonded to the annular carbon atoms and is an aliphatic
radical of from 1 to 8 carbon atoms and from 0 to 3 heteroatoms
which are oxygen, sulfur or nitrogen, or aromatic hydrocarbon of
from 6 to 9 carbon atoms;
X.sup.6 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof or, when R.sup.6 is aromatic hydrocarbon,
diazo;
when other than --R.sup.6 --X.sup.6 --, Z.sup.7, Z.sup.8 and
Z.sup.9 are hydrogen;
Y.sup.6 is hydrogen or hydroxyl; and
n.sup.7 is on the average in the range of from 1 to 14.
15. A morphine conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 morphine groups, wherein the morphine is joined
at the O.sup.3 position to an acetimidate linking group.
16. A morphine conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 morphine groups, wherein the morphine is joined
at the O.sup.3 site to an acetyl linking group.
17. A phenobarbital conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 phenobarbital groups, wherein the phenobarbital
is joined at the 1 nitrogen position through an acetimidate linking
group.
18. A phenobarbital conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 phenobarbital groups wherein the phenobarbital
is joined at the 1 nitrogen position to an ethyleneoxyacetimidate
linking group.
19. A phenobarbital conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 phenobarbital groups wherein the phenobarbital
is joined at the 5 position to a .alpha.-crotonyl linking
group.
20. A diphenylhydantoin conjugate to glucose-6-phosphate
dehydrogenase having from 1 to 14 diphenylhydantoin groups wherein
the diphenylhydantoin is joined at the 3 nitrogen to an acetimidate
linking group.
21. An estradiol conjugate to glucose-6-phosphate dehydrogenase
having from 1 to 14 estradiol groups, wherein the estradiol is
joined at the O.sup.3 position to an acetimidate linking group.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
Immunoassays have shown themselves to be extremely versatile in
allowing for methods to determine the presence of a particular
substance, even when a wide variety of other materials of similar
or different structure are present in the unknown sample. The
immunoassays rely on the ability of an antibody to specifically
detect or bind to an haptenic organic compound, while not
interacting with other compounds. The divalent nature of the
antibody and its high molecular weight, 150,000 or greater, allow
for a sufficient change in the compound or environment of the
compound to permit a discrimination between a compound which is
bound and a compound which is not bound to antibody. Among various
immunoassays involving antibodies are radioimmunoassay, spin
immunoassays, available under the trademark FRAT, supplied by Syva
Company, homogeneous enzyme immunoassay, available under the
trademark EMIT, supplied by Syva Company, and
hemeagglutination.
The enzyme immunoassay is extremely versatile in permitting
spectrophotometric determinations. The immunoassay employs an
enzyme to which the organic compound to be determined is
conjugated. The organic compound is conjugated at a position where
when bound to antibody, the activity of the enzyme is substantially
reduced. To the extent that the unknown sample contains the same
organic compound, the amount of antibody available for binding to
the organic compound conjugated to the enzyme is reduced.
Therefore, by analyzing for enzymatic activity, a significant
increase in enzymatic activity over the enzymatic activity in the
absence of the unknown indicates the presence of the organic
compound in the unknown.
The sensitivity of the homogeneous enzyme immunoassay is based to a
substantial degree on the activity of the enzyme when conjugated
and the degree of inhibitability when antibody is bound to the
organic compound conjugated to the enzyme. It is, therefore,
desirable to have an enzyme which not only has a high turnover rate
initially, but retains a substantial proportion of this turnover
rate after conjugation, and is strongly inhibited when antibody is
bound to the organic compound which is conjugated to the enzyme.
Also, the enzyme should allow for strong specific binding of
antibody to the conjugated organic compound.
2. Description of the Prior Art
An homogeneous enzyme immunoassay system has been sold under the
trademark EMIT employing haptens conjugated to lysozyme, where the
enzymatic activity is determined by the reduction in turbidity as a
result of lysis of bacterial walls. Numerous publications
concerning the system have issued since June of 1971, see for
example, Rubenstein, et al., Biochem & Biophysical Res. Comm.
47 846 (1972). U.S. Pat. No. 3,654,090 teaches a heterogeneous
immunoassay employing such enzymes as peroxidase and
amyloglucosidase.
SUMMARY OF THE INVENTION
Haptenic conjugates to glucose-6-phosphate dehydrogenase are
provided for employment in homogeneous enzyme immunoassays to
provide high sensitivity in detecting extremely small amounts of
organic materials. One or more of the haptens (hereinafter referred
to as ligands) are conjugated by relatively short chains or linking
groups to the glucose-6-phosphate dehydrogenase to provide a
product still retaining a substantial proportion of the original
enzyme activity and having a high degree of inhibitability, usually
in excess of 50% of the original activity of the conjugated
glucose-6-phosphate dehydrogenase. The linking chains normally
employ a non-oxocarbonyl group or a covalent bond to saturated
carbon as the linking group to the enzyme.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Haptenic conjugated glucose-6-phosphate dehydrogenase is provided
having from about 1 to 18, usually from about 2 to 14, and more
usually from about 2 to 12 ligands, normally the majority or all of
the ligands being bonded to amino groups, particularly of lysine.
The haptens or ligands will normally have molecular weights of at
least 125 and generally not exceeding 1,000, more usually not
exceeding 800, and frequently not exceeding 600 molecular weight.
The ligands will have at least one heteroatom and may have two or
more heteroatoms, which will normally be oxygen, nitrogen and
sulfur, although halogen, particularly chlorine and iodine may also
be present. The ligands for the most part will be naturally
occurring, physiologically active compounds and synthetic drugs,
which will be modified to the extent necessary for conjugation to
the glucose-6-phosphate dehydrogenase.
The enzyme conjugates of this invention will for the most part have
the following formula:
G--6--PDH } (X--R--Y).sub.n
wherein:
G--6--pdh intends glucose-6-phosphate dehydrogenase;
n indicates the average number of groups bonded to the G--6--PDH
and will generally be in the range of 1 to 18, more usually in the
range of 2 to 14, and particularly in the range of 2 to 12;
R is a bond or a hydrocarbon (aliphatic, alicyclic or aromatic),
particularly aliphatic, linking group, either branched or straight
chain, of from 0 to 1 rings and of from 1 to 8 carbon atoms, more
usually of from 1 to 6 carbon atoms, and preferably of from 1 to 4
carbon atoms, usually having from 0 to 1 site of aliphatic
unsaturation, and more usually aliphatically saturated, or
substituted hydrocarbon group having from 0 to 3 heteroatoms, more
usually 0 to 2 heteroatoms, which are oxygen, sulfur and nitrogen,
more usually oxygen and nitrogen (atomic number 7-8); and
Y is a ligand of at least 125 molecular weight, usually not greater
than 1,000 molecular weight, more usually not greater than 800
molecular weight, and generally not exceeding 600 molecular weight,
and has at least one common epitope to a naturally occurring
physiologically active compound or synthetic drug, usually
differing from the naturally occurring physiologically active
compound or synthetic drug by replacement of a hydrogen or
modification of a functionality such as an olefin, oxo or the like,
to provide a site for bonding of R to the ligand; and
X is a bond, a non-oxocarbonyl group, including the nitrogen and
sulfur analogs thereof, i.e. imino and thiocarbonyl, or diazo when
R is arylene, aralkylene or a bond and the nitrogen of the diazo
group is bonded to an aromatic annular carbon atom.
X may be bonded to R through carbon or a heteroatom, particularly
nitrogen. Since sulfur bonds and certain oxygen bonds, e.g. esters
will tend to be reactive, these will usually be avoided. Oxygen
will normally be present in the linking group as a carbonyl (oxo or
non-oxo) or oxyether. Sulfur will normally be present in the
linking group as thiocarbonyl or thioether. Nitrogen will normally
be present in the linking group as tertiary or quaternary amino,
diazo or bonded to a non-oxocarbonyl, including the amino and
thioanalogs thereof.
Usually, when R is aromatic (aromatic includes arylene, aralkylene
or alkarylene), R will be bonded to Y through a heteroatom,
particularly ethereal oxygen, i.e. oxy. R groups of particular
interest are methylene or polymethylene, i.e. (CH.sub.2).sub.p,
where p is an integer in the range of 1 to 6, alkyleneoxyalkylene,
i.e. (CH.sub.2).sub.q O(CH.sub.2).sub.r, where q and r are the same
or different and are integers in the range of 1 to 3, there being
at least two methylene groups between heteroatoms, or
(CH.sub.2).sub.s NH, where s is an integer in the range of 1 to 6,
usually 1 to 4, there being at least two methylene groups between
heteroatoms.
When X is other than a bond, X will normally have one of the
following formulae: ##SPC1##
and will preferably be either the oxygen or the imino
non-oxocarbonyl.
The groups for --R--X-- will include ethylene, propylene, butylene,
hexylene, phenylene, p-benzylylene, .alpha.-carboxymethine,
carbamoylmethylene (--NHCOCH.sub.2 --), iminoxyacetyl (=NOCH.sub.2
CO--), thrioacetyl, p-oxybenzyl, maleidioyl, succindioyl,
oxoethylene (--OCCH.sub.2 --), 1-oxobutylene(--OCCH.sub.2 CH.sub.2
CH.sub.2), ethyleneoxyacetyl, propyleneoxyacetyl, N-methyl
3-aza-1-imino-pentylene-(--(NH=C)--CH.sub.2 N(CH.sub.3)CH.sub.2
CH.sub.2 CH.sub.2 --), ethylenecarbamoyl (--(O=C)NHCH.sub.2
CH.sub.2 --) propylenethiocarbamoyl (--(S--C)NHCH.sub.2 CH.sub.2
CH.sub.2 --), ethyleneoxyacetimidate,
ethyleneoxyethylenethiocarbamoyl, propyleneoxypropylenecarbamoyl
and diethyleneoxyacetimidoyl.
Turning now to consideration of individual compounds, the first
group of compounds are the alkaloids. Of particular interest among
the alkaloids are the opiate alkaloids which will have for the most
part the following formula: ##SPC2##
wherein:
T is hydrogen or acetyl, usually hydrogen,
n.sup.1 is on the average 1 to 14, usually 1 to 12, more usually 2
to 12;
R.sup.1 may be the same as R, but will usually be either (1) an
aliphatic group, either branched or straight chain, having from 0
to 1 site of aliphatic unsaturation, e.g. ethylenic and of from 1
to 8 carbon atoms, more usually of from 1 to 6 carbon atoms, and
preferably of from 1 to 4 carbon atoms and has from 0 to 3, usually
0 to 2 heteroatoms, which are oxygen, sulfur or nitrogen, usually
oxygen and nitrogen, and bonded to X with other than sulfur and
oxygen, and bonded to oxygen through carbon, wherein the oxygen is
present as oxocarbonyl or oxy, particularly ether, and the nitrogen
is present as tertiary amino; or (2) aromatic hydrocarbon, e.g.
arylene, alkarylene or aralkylene of from 6 to 9 carbon atoms;
and
X.sup.1 is a bond, non-oxocarbonyl (including thio and imino
analogs thereof), or diazo, when bonded to an aromatic annular
carbon atoms, i.e. when R.sup.1 is aromatic hydrocarbon.
Illustrative groups for --R.sup.1 --X.sup.1 -- include
carboxymethyl, imidoylmethyl, thiocarbamoylethyl, diazophenyl,
ethylene, ethyleneoxyethylene, carboxymethyleneoxyethyl,
2-(1-carboxypropylene) and N-methyl imidoylmethylaminoethyl.
The next group of compounds are cyclic lactams or urea compounds of
the following formula: ##SPC3##
wherein:
n.sup.2 is on the average from 1 to 14, usually 1 to 12, more
usually of from 2 to 12;
T.sup.1 and T.sup.2 are hydrocarbon of from 1 to 7 carbon atoms,
more usually of from 1 to 6 carbon atoms, and from 0 to 1 site of
aliphatic unsaturation, e.g. ethylenic, including ethyl, n-butyl,
.alpha.-methylbutyl, isoamyl, allyl, hexyl, .DELTA..sup.1
-cyclohexenyl and phenyl, and when m is 0 phenyl;
one of W and W.sup.1 is --R.sup.2 --X.sup.2 -- and the other is
hydrogen.
Z is oxygen, with the proviso that Z may be H.sub.2 when one of
T.sup.1 and T.sup.2 is phenyl, e.g. primidone.
m is 0 when the compound is diphenylhydantoin, and 1 when the
compound is a barbiturate or Z is H.sub.2 ;
R.sup.2 may be the same as R but is usually an aliphatic group of
from 1 to 8 carbon atoms, usually of from 1 to 6 carbon atoms, and
preferably of from 1 to 4 carbon atoms, and from 0 to 3
heteroatoms, usually of from 0 to 2 heteroatoms, and from 0 to 1
site of aliphatic unsaturation, where the heteroatoms are oxygen,
sulfur and nitrogen, usually oxygen and nitrogen, R.sup.2 being
bonded to nitrogen through an aliphatically saturated carbon atom
and to X.sup.2 with other than oxygen and sulfur; or aromatic
hydrocarbon of from 6 to 9 carbon atoms; and
X.sup.2 is a bond, non-oxocarbonyl including the nitrogen and
thioanalogs thereof, or diazo when bonded to an aromatic annular
carbon atom.
Illustrative groups for --R.sup.2 --X.sup.2 -- include diazo,
methylene, ethylene, butylene, ethyleneoxyethyl, acetyl,
imidoylmethyl, propyleneoxyacetimidoyl, carboxyvinylene,
carboxypropylene, imidoylbutylene, N-methyl ethyleneaminoethyl,
N-methyl ethyleneaminoacetyl, and 1-(1-carboxyethylene).
The next group of compounds are the steroids, which include the
estrogens, gestogens, androgens, adrenocortical hormones
(glucocorticoids and mineral corticoids and bile acids). Of
particular interest are the sex hormones and the adrenocortical
hormones. The steroids will be divided into two groups depending on
whether the A ring is aromatic or cycloaliphatic.
For the most part, those compounds which are gestogens, androgens,
or adrenocortical hormones will come within the following formula:
##SPC4##
wherein:
one of Z.sup.1, Z.sup.2, and Z.sup.3 is --R.sup.3 --X.sup.3 --,
wherein the R.sup.3 may be singly or doubly bonded to the annular
carbon atom. R.sup.3 may be the same as R, but is usually an
aliphatic group having from 0 to 1 site of aliphatic unsaturation
and of from 1 to 8 carbon atoms, usually of from 1 to 6 carbon
atoms, and more usually of from 1 to 4 carbon atoms, having from 0
to 3 heteroatoms which are oxygen, nitrogen and sulfur, usually
oxygen and nitrogen, R.sup.3 being bonded to X.sup.3 at other than
oxygen and sulfur; or atomatic hydrocarbon of from 6 to 8 carbon
atoms;
X.sup.3 is a bond, non-oxocarbonyl including the nitrogen and
sulfur analogs thereof, or diazo, when bonded to an aromatic
annular carbon atom;
when other than --R.sup.3 --X.sup.3 --, Z.sup.2 and Z.sup.3 are
hydrogen;
when the compound is a gestogen, there is from 0 to 1 site of
ethylenic unsaturation in the .DELTA..sup.4 or .DELTA..sup.5
position, and when other than --R.sup.3 --X.sup.3, Z.sup.1 is
hydroxyl or oxo;
Y.sup.1 is acetyl; and
Y.sup.2 and Y.sup.3 are hydrogen;
when the compound is an androgen, when other than --R.sup.3
--X.sup.3, Z.sup.1 is oxo;
Y.sup.1 is hydroxyl; and
Y.sup.2 and Y.sup.3 are hydrogen;
when the compound is an adrenocortical hormone:
when other than --R.sup.3 --X.sup.3, Z.sup.1 is oxo;
Y.sup.1 is hydroxyacetyl;
Y.sup.2 is hydrogen or hydroxyl; and
Y.sup.3 is hydroxy or oxo;
n.sup.3 on the average will be in the range of 1 to 14, usually 1
to 12, more usually in the range of 2 to 12.
When the compound is an estrogen and the A ring is aromatic, the
compounds will for the most part have the following formula:
##SPC5##
wherein:
one of Z.sup.4, Z.sup.5, and Z.sup.6 is --R.sup.4 --X.sup.4 --,
wherein when Z.sup.4 or Z.sup.6 is --R.sup.4 --X.sup.4 --, R.sup.4
may be singly or doubly bonded to the annular carbon atom, wherein
R.sup.4 may be the same as R, but is usually an aliphatic radical
having from 0 to 1 site of aliphatic unsaturation and of from 1 to
8 carbon atoms, usually of from 1 to 6 carbon atoms, and more
usually of from 1 to 4 carbon atoms and from 0 to 3 heteroatoms
which are oxygen, nitrogen and sulfur, more usually oxygen and
nitrogen, or aromatic hydrocarbon of from 6 to 8 carbon atoms, and
X.sup.4 is non-oxocarbonyl including the nitrogen and sulfur
analogs thereof, or diazo when bonded to an aromatic annular carbon
atom;
when other than --R.sup.4 --X.sup.4 --, Z.sup.4, Z.sup.5 and
Z.sup.6 will be hydrogen;
Y.sup.4 is hydrogen or hydroxyl; and
n.sup.4 on the average is in the range of from 1 to 14, usually 1
to 12, more usually in the range of from 2 to 12.
Illustrative groups for --R.sup.3 --X.sup.3 -- and --R.sup.4
--X.sup.4 -- include ethylene, ethyleneoxyacetyl, iminoxyacetyl,
p-phenylenediazo, ethylenethiocarbamoyl, carboxybutylene,
imidoylpropylene, p-diazobenzyl and thioetheracetyl.
The next compounds are methadone derivatives which will, for the
most part, have the following formula: ##SPC6##
wherein:
R.sup.5 may be the same as R, but is usually an aliphatic radical
of from 1 to 8 carbon atoms, usually of from 1 to 6 carbon atoms,
and more usually of from 1 to 4 carbon atoms; and from 0 to 3
heteroatoms which are oxygen, sulfur and nitrogen, particularly
oxygen and nitrogen;
X.sup.5 is non-oxocarbonyl including the nitrogen and sulfur
analogs thereof; and
n.sup.5 is on the average in the range of from 1 to 14, usually 1
to 12, more usually in the range of from 2 to 12.
The next group of compounds are associated with steroids and are
cardiac glycosides of which digoxigenin and digoxin are well known
members. For the most part, the compounds will have the following
formula: ##SPC7##
wherein:
one of Z.sup.7, Z.sup.8, and Z.sup.9 is --R.sup.6 --X.sup.6 --,
wherein when Z.sup.8 and Z.sup.9 are R.sup.6, R.sup.6 may be singly
or doubly bonded to the annular carbon atoms, wherein R.sup.6 may
be the same as R, but is usually an aliphatic radical having from 0
to 1 site of aliphatic unsaturation and of from 1 to 8 carbon
atoms, usually of from 1 to 6 carbon atoms, and more usually of
from 1 to 4 carbon atoms and from 0 to 3 heteroatoms, usually of
from 0 to 2 heteroatoms, which are oxygen, sulfur or nitrogen,
preferably oxygen and nitrogen, and X.sup.6 is non-oxocarbonyl
including the nitrogen and sulfur analogs thereof, or atomatic
hydrocarbon of from 6 to 9 carbon atoms.
when other than --R.sup.6 --X.sup.6 --, Z.sup.7, Z.sup.8 and
Z.sup.9 are hydrogen;
Y.sup.5 is hydrogen or hydroxyl; and
n.sup.6 is on the average in the range of from 1 to 14, usually 1
to 12, more usually in the range of from 2 to 12.
The same groups illustrative of --R.sup.3 --X.sup.3 -- are also
illustrative of --R.sup.6 --X.sup.6 --.
While various sources of glucose-6-phosphate dehydrogenase may be
employed, a particularly desirable source for the primary use for
the subject compounds is the bacterium L.mesenteroides. The
particular value of the G--6--PDH from this bacterium is that it is
able to utilize both NADP and NAD. Since G--6--PDH from animal
sources normally is able to utilize only NADP, one can limit
interference from endogenous G--6--PDH by employing NAD as the
co-factor, when the subject compounds are used in immunoassays.
In preparing the conjugates, it is desirable that at least 20,
preferably at least 40 and particularly preferred at least 50% of
the original enzyme activity is retained. Furthermore, the enzyme
is substituted in such a manner so that when one or more groups are
bonded to the enzyme, and are bound by antibody, the activity of
the enzyme is reduced by at least 30% of its original activity
after conjugation, usually at least 40%, and preferably by at least
50%.
Various ways can be employed for conjugating the various compounds
or ligands to the glucose-6-phosphate dehydrogenase. The conditions
employed will normally reflect the particular functionality which
is employed in forming a bond to the glucose-6-phosphate
dehydrogenase. The functionalities which find primary use are the
mixed anhydride employing an alkyl chloroformate, acyl azide, the
imidate ester, thioimidate, isothiocyanate, reductive alkylation
with an aldehyde, or an isocyanate. Normally, the groups will be
bonded to available amino groups of lysine as the major mode of
conjugation, and therefore amides, amidines, ureas, thioureas, and
alkylamines will be formed.
The reaction mixture will normally be buffered to a pH in the range
of 5 to 10, more usually in the range of 6 to 9. Various buffers
may be used, such as phosphate, carbonate, Tris, and the like. An
aqueous solvent will normally be used, and a preferred solvent
includes from about 10 to 40 weight percent of an oxyethylene
alcohol or ether having from 1 to 3 oxyethylene units. Particularly
useful is carbitol. The temperatures will normally be at or above
-5.degree.C and generally less than about 40.degree.C, usually from
about 0.degree. to 25.degree.C.
The concentration of the enzyme will vary widely, generally ranging
from about 0.05 to 5, more usually from about 0.1 to 10mg/ml. The
amount of ligand to be conjugated will vary, depending on the
ligand enzyme ratio which is desired.
EXPERIMENTAL
The following examples are offered by way of illustration and not
by way of limitation.
(All temperatures not otherwise indicated are in centigrade).
EXAMPLE I
A survey was carried out employing the isobutyl chloroformate mixed
anhydride of O.sup.3 -carboxymethylmorphine and methyl O.sup.3
-morphinoxyacetimidate.
The conjugations were carried out as follows. The enzyme was
obtained as a 4.8 mg/ml solution in 30% glycerol. Specific activity
was 561 IU/mg protein for NAD reduction at 30.degree.. The glycerol
solution was dialyzed against 0.05M sodium phosphate, pH 7.5 and
diluted with that buffer to a concentration of 2 mg/ml. The pH was
adjusted to 7.0 with 1M HCl. To one ml of this cooled (4.degree.)
stirred enzyme solution was added in five portions during 5
minutes, 37.5.mu.l of a 0.2M solution of the mixed anhydride
(N-methyl-.sup.14 C) in dimethylformamide. After each addition, the
pH rose slightly and was readjusted to 7 with 1M HCl. The solution
was then maintained for 5 hours at 4.degree. and dialyzed
exhaustively against 0.55M Tris-HCl, pH 7.9. The resulting solution
was diluted to 2ml with dialysis buffer. Scintillation counting was
then employed to determine the number of ligands conjugated to the
enzyme on the average.
To determine the activity of the enzyme and its inhibition,
immunoassays were carried out. The assay mixture had a total volume
of 1ml and was prepared from 20.mu.l of 0.1M NAD in water (pH 5-6),
50.mu.l of 0.066M glucose-6-phosphate in assay buffer, and enzyme
solution. The remaining volume was made up by the assay buffer
which was 0.055M Tris-HCl, pH 7.9. The mixture was incubated for 60
seconds in a spectrophotometer flow cell at 30.degree., and the
increase in absorbance at 350nm was then read over a 1 minute
interval. 10.mu.l of the above enzyme solution diluted 1:100 in
assay buffer containing 0.1% RSA (rabbit serum albumin) gave a rate
of 0.160 optical density units per min. (OD/min.). This
corresponded to 52% of the activity of the native enzyme. Addition
of a large excess of an antiopiate gamma-globulin preparation
(5.mu.l of a solution that was 8 .times. 10.sup.-.sup.5 M in
binding sites) prior to addition of the enzyme solution to the
assay mixture reduced the activity by 78% (0.0350D/min.) When
50.mu.l of 10.sup.-.sup.4 M morphine and water was added to the
substrates prior to addition of the antibody and enzyme, the total
enzyme activity was recovered.
A number of preparations were carried out using differing buffers,
pH's, and mole ratios. Also, in some instances, the enzyme
substrates were included to determine their effect on deactivation.
It was found that above 14 ligands per enzyme molecule on the
average, substantial deactivation of the enzyme had occurred. The
following table indicates the results:
TABLE I
__________________________________________________________________________
Reagent.sup.i Buffer.sup.ii pH G6PDH Reagent Deactivation.sup.iii
Inhibition.sup.iv Ligand.sup.v moles .times. 10.sup..sup.-8 moles
.times. 10.sup..sup.-6 % % G6-PDH
__________________________________________________________________________
a 1 P-C 9 3.85 1.25 56 52 7.5 b 2 P 8.5 3.85 5.0 41 48 4.7 c 2 P
8.5 3.85 15 66 80 10.5 d 2* T-M 8.5 3.85 15 45 75 9.5 e 2+ T-M 8.5
3.85 15 48 82 11.5 f 2 T-M 8.5 3.85 15 63 87 12.0 g 2 P 6.0 1.92
7.5 16 9 1.3 h 2 P 7.0 1.92 7.5 52 78 13
__________________________________________________________________________
* Prior to conjugation added G-6-P to 50mM and NAD to 40mM. The pH
required adjustment to 8.5 + Prior to conjugation added G-6-P to
50mM and NAD to 40mN. .degree. G-6-PDH had activity of 561 IU/mg,
while other G-6-PDH had activity of 460 IU/mg. .sup.i 1- O.sup.3
-carboxymethylmorphine; 2- methyl O.sup.3 -morphinoxyacetimidate
.sup.ii P-C --0.5M sodium phosphate-0.5M sodium carbonate; P --0.5M
sodium phosphate; T --M --0.055m Tris-HCl-0.003M magnesium chloride
.sup.iii % of original enzyme activity after conjugation and
dialysis .sup.iv Maximum inhibition by excess antimorphine .sup.v
Both ligands contain .sup.14 C. Determined by liquid scintillation
counting of aliquots of product.
EXAMPLE II
A general conjugation procedure was employed as follows: Commercial
G-6-PDH 4.9mg/ml (Beckman Microbics) was dialyzed against 0.055M
Tris-HCl buffer, pH 7.9. The concentration subsequent to dialysis
was adjusted to 2mg/ml or 1 .times. 10.sup.-.sup.8 moles of enzyme
per milliter. A 0.5ml aliquot of the enzyme solution was placed in
a glass vial equipped with a micromagnetic stirring bar and a pH
electrode and cooled in an ice bath. To the stirring solution was
added 20mg NADH (0.026mmole) and 11mg of glucose-6-phosphate
(0.034mmole) as crystalline solids. To the cold stirring solution
was added slowly by means of a syringe needle below the liquid
surface, sufficient carbitol to provide 25% by volume
(approximately 125.mu.l). To this solution was then added by means
of a syringe, the ligand at approximately 0.1M in carbitol. The
reaction mixture was then incubated and aliquots withdrawn, diluted
and the rates determined as to deactivation and inhibition.
The assay procedure was as follows. 2 parts of a solution 0.1M NAD
in water at pH 5-6 was combined with 3 parts by volume of 0.11M
glucose-6-phosphate in 0.055M Tris-HCl buffer, pH 7.9. An aliquot
from the conjugation reaction mixture was diluted 1:1,000 with the
above indicated buffer. An assay solution was formed from 50.mu.l
of the G--6--P/NAD solution, 750ml of buffer, 50.mu.l of buffer or
buffer containing antibody, depending on whether the deactivation
or inhibitability was being determined, and 50.mu.l of the enzyme
conjugate or enzyme control. Portions of buffer were employed to
insure quantitative transfers. The solution was aspirated into a
spectrometer and the rate of NADH production was followed at 340nm
at 37.degree.. The change in OD per min. was determined between the
second and third minutes.
The following table indicates the results obtained. ##SPC8##
EXAMPLE III
A number of experiments were carried out following the following
procedure. A 500.mu.l solution at a concentration of 2mg/ml of
G-6-PDH which had been freshly dialyzed in 0.055M Tris buffer, pH
7.9 and then diluted to the indicated concentration was cooled in
an ice bath and 100.mu.l of the ligand to be conjugated added over
a 5 minute period. A syringe was used for the addition of the
ligand, with the tip of the syringe kept underneath the surface of
the reaction mixture near the stirring bar.
As soon as the addition of the ligand was complete, an aliquot was
taken out and diluted 1:1,000 with the above buffer containing 0.1
weight % RSA. Subsequently, additional aliquots were removed and
assayed.
The assay procedure was as follows. Approximately, a 10.mu.l
aliquot of the reaction mixture was added to a 0.5ml portion of the
buffer containing 0.1 weight % RSA and then further diluted, by
taking 20.mu.l of this solution and adding it to 0.4ml of the same
buffer. This provides a 1:1,000 dilution.
Sufficient buffer was initially added to the cup to provide a final
volume of 1ml. To the buffer was then added 70.mu.l of 2:3 parts by
volume of 0.066M G--6--P in 0.055M Tris, pH 7.9, 50.mu.l of stock
antimorphine solution and 50.mu.l of the above diluted enzyme
reaction mixture. The solution was aspirated into a spectrometer
and followed at 340nm for the first 40 secs.
The following table indicates the results obtained with a variety
of haptens. ##SPC9##
EXAMPLE IV
5-(N-Phenobarbityl)pentanoic acid conjugation to
glucose-6-phosphate dehydrogenase
A. Into a reaction vessel was introduced 0.5ml of dimethylformamide
(DMF), 16.6mg of 5-(N-phenobarbityl)pentanoic acid and 6.95.mu.l of
triethylamine and cooled to -10.degree.. To the solution was then
added 8.5.mu.l of carbityl chloroformate, the mixture warmed to
0.degree. and allowed to stand for 45 minutes, at which time it was
ready for use.
B. Varying ratios of phenobarbital were combined with
glucose-6-phosphate dehydrogenase in differing buffers. The
following is the general procedure.
Into a reaction vessel was introduced 0.25ml of an aqueous buffered
solution containing 0.5mg of glucose-6-phosphate dehydrogenase,
5.23mg of glucose-6-phosphate and 9.9mg of NADH. To the mixture was
then added carbitol followed by an aliquot of the solution,
prepared as described in part (A), and carbonate buffer, using a
syringe with the needle below the surface. The reaction was found
to occur in less than 30 minutes, although some reaction times were
allowed to proceed for as long as 2 hours. At the end of the
reaction, any precipitate or cloudiness was substantially removed
by centrifugation of the sample. The assay employed followed the
procedure described in Example III.
The following table indicates the materials employed and the
percent inhibitability of the enzyme conjugate.
TABLE IV
__________________________________________________________________________
Phenobarbityl 0.1M aq. Enzyme.sup.1 mixed Anhydride Carbitol
carbonate Time P/E.sup.2 % Buffer .mu.l .mu.l .mu.l pH hrs.
mole-ratio D.sup.3 I.sup.4
__________________________________________________________________________
1. T 10 65 50 9.0 .ltoreq.0.5 200 63.6 54.1 2. T 2.5 72.5 50 7.9 "
50 16.6 10 3. T 5 70 .about.35 9.0 " 100 50.6 34.4 4. T 2.5 72.5 50
7.9 " 50 16.6 10 5. T 10 65 50 9.0 2 200 55 6. T 2.5 72.5 50 7.9 2
50 10 7. T 5 70 .about.35 9.0 2 100 37 8. T 2.5 72.5 50 7.9 2 50 7
9. P 3.75 71.3 50 10 .ltoreq.0.5 75 22 10. P 7.5 67.5 50 9 " 150 70
11. P 3.75 71.3 50 10 2 75 26 12. P 7.5 67.5 50 9 2 150 66
__________________________________________________________________________
1. T tris-HCl 0.055M, pH 8.4? P phosphate 0.01M, pH 2. P/E --
phenobarbital/enzyme 3. deactivation -- based on activity of enzyme
prior to conjugation. 4. inhibition -- based on activity of enzyme
in presence of excess of antiphenobarbital as compared to activity
of conjugated enzyme
EXAMPLE V
4-(5'-Phenylbarbituryl-5')crotonic acid conjugate to
glucose-6-phosphate dehydrogenase
A. Into a reaction flask fitted with a drying tube was introduced
250.mu.l of DMF, 15.8mg of 4-(5'-phenylbarbituryl-5') crotonic
acid, and 6.8.mu.l of triethylamine and cooled to -8.degree.. To
the mixture was slowly added 9.3.mu.l of carbityl chloroformate
while maintained at a temperature of -4.degree..
B. Two reactions were carried out, each reaction mixture employing
one ml of 0.055M tris buffer, pH 7.9, containing 1.55mg of G6PDH,
353.mu.l of carbitol, and 25.mu.l of 1N sodium hydroxide following
the previously described procedure in Example IV. In the first
reaction mixture, 25.mu.l of the above mixed anhydride was
employed, while in the second reaction mixture 29.mu.l of the above
mixed anhydride was employed. Upon assaying for the enzyme as
described previously, the percent deactivation was found to be 69.4
and 69.9 respectively, while the percent inhibition was found to be
74.4 and 75%, respectively.
EXAMPLE VI
5-(N-Diphenylhydantoinyl)pentanoic acid conjugate to
glucose-6-phosphate dehydrogenase
A. Into a reaction vessel was introduced 0.125ml DMF 17.8mg of
5-(N-diphenylhydantoinyl)pentanoic acid and 6.8.mu.l of
triethylamine, the mixture cooled to -10.degree., and 9.3.mu.l of
carbityl chloroformate added slowly while maintaining the
temperature below 0.degree..
B. Following the previously described procedure in Example IV, into
a reaction flask was introduced 0.595ml of tris buffer, pH 7.9
containing G6PDH at a concentration of 0.955 mg/ml, 5.25mg of
glucose-6-phosphate, 9.9mg of NADH and 150.mu.l of carbitol, and
the pH adjusted to 8.5 with 1N sodium hydroxide. To the mixture was
then added 2.mu.l of the above mixed anhydride with the pH being
brought to 9.5, the total amount of 1N sodium hydroxide added being
116.mu.l. The following table indicates the percent deactivation
and inhibitability of the resulting product.
TABLE V ______________________________________ % Deactivation
Inhibition 1. 69 48 2. 64.2 52.2
______________________________________
EXAMPLE VII
2-(N-Diphenylhydantoinyl)ethoxyacetic acid conjugate to
glucose-6-phosphate dehydrogenase
A. To a vessel containing 17mg of dried
2-(N-diphenylhydantoinyl)ethoxyacetic acid was added 250mg of dry
DMF. To the solution was then added by syringe 9.mu.l of
triethylamine. After cooling to 0.degree., 9.mu.l of carbityl
chloroformate was added by syringe. After stirring for 1 hour at
0.degree., a white precipitate formed. The supernatant was used as
is and was 0.2M in mixed anhydride.
B. To 0.5ml of 0.01M phosphate buffer, pH 8, containing 0.5mg of
glucose-6-phosphate dehydrogenase was added 10mg of NADH and 5mg of
G--6--P. After cooling in an ice bath, 200.mu.l of carbitol
(Dowanol-DB) was added slowly by syringe below the surface of the
solution. The pH was monitored and adjusted by the addition of 0.1N
sodium carbonate to 9.14. To the solution was then added 15.mu.l of
the above mixed anhydride solution in the same manner as the
carbitol, with the pH dropping to 8.98. After 10 minutes from the
addition, the solution was diluted with 1ml Tris-HCl, pH 7.9 buffer
and assayed. Following the procedure described previously in
Example IV, the percent deactivation was found to be 29, while the
percent inhibitability was found to be 47.
EXAMPLE VIII
2-(N-Diphenylhydantoinyl)propionic acid conjugate to
glucose-6-phosphate dehydrogenase
A. To a flask containing 16.2mg of
2-(N-diphenylhydantoinyl)propionic acid was added under nitrogen
250.mu.l of DMF and 7.05.mu.l of triethylamine. After cooling the
mixture to -4.degree., 9.25.mu.l of carbityl chloroformate was
added, and the mixture allowed to react at -3.degree. for 1
hour.
B. To 0.5ml of Tris-HCl buffer, pH 7.9, containing 0.732mg of
glucose-6-phosphate dehydrogenase, 19.8mg of NADH and 10.5mg of
G--6--P was added slowly by syringe below the surface of the
reaction mixture, 9.5.mu.l of the above prepared mixed anhydride.
During the addition, the pH was maintained at 9.0 by the addition
of 0.1N NaOH. Employing the procedure described previously in
Example IV, the enzyme was then assayed and was shown to be 59%
deactivated and 53% inhibitable.
Reagents were prepared as follows. Where the preparation is not
available in the literature, an exemplary preparation is
provided.
EXAMPLE A
Carbityl N-phenobarbitylacetimidate
1. To a solution of 2g sodium phenobarbital in 10ml of DMSO,
500.mu.l of chloroacetonitrile in 10ml of DMSO was added over a
1-hour period under nitrogen. After stirring for an additional 30
minutes, the mixture was poured into 100ml 5 weight % sodium
carbonate and washed with chloroform. The chloroform was washed
once with 5 weight % sodium carbonate and the combined carbonate
solutions acidified with 6N HCl, followed by extracting three times
with chloroform. After drying the combined chloroform extracts, the
chloroform was evaporated to leave an oil. The oil was
chromatographed on 75g silica gel-HF with 15% ethyl ether in
methylene chloride. The fractions containing the product were
combined, evaporated, and the residue crystallized from
chloroform-hexane to yield 650mg product (30% yield). m.p.
152.degree.-154.degree..
2. To 2ml of carbitol was added 23mg sodium hydride under nitrogen
and the mixture was allowed to stand until the sodium hydride had
reacted. To the alkoxide was added 118mg of the above product and
the mixture stirred at room temperature under nitrogen for 24
hours.
EXAMPLE B
Carbityl 2-(N-phenobarbityl)ethoxyacetimidate
1. To a solution of 635mg of sodium phenobarbital in 7ml of dry
DMSO heated to 60.degree. under nitrogen was added 345.mu.l
2-chloroethoxyacetonitrile and 5mg potassium iodide and the mixture
stirred overnight under nitrogen at 60.degree.-70.degree.. The
reaction mixture was then stripped of volatiles at 60.degree. at
0.2mm Hg, the residue dissolved in ethyl ether and extracted 5
times with 5 weight % sodium carbonate. The alkaline extracts were
acidified, extracted three times with ethyl ether and the combined
ether extracts washed with brine, dried, and stripped to yield an
oil. The oil was purified on preparative TLC with 4:1 ethyl ether:
petroleum ether. An oil weighing 237mg was isolated.
2. Into 1ml of carbitol was dissolved 8.5mg of sodium hydride under
nitrogen. To the mixture was 42mg of the above product and the
mixture allowed to stand for 2 days at room temperature under
nitrogen.
EXAMPLE C
Carbityl N-diphenylhydantoinylacetimidate
1. A solution of 500mg of sodium diphenylhydantoin and 415mg of
chloroacetonitrile in 20ml of DMF under nitrogen was heated at
40.degree.-50.degree. for 66 hours. At the end of this time, the
mixture was evaporated to near dryness, water added and the aqueous
solution extracted with chloroform. The chloroform was first washed
with water followed by 1N sodium hydroxide and then dried and
evaporated. The resulting oil was crystallized from absolute
ethanol to yield 255mg. m.p. 125.degree.-7.degree..
2. Approximately 1mg of sodium hydride was dissolved in 0.5ml
carbitol to which was added 25mg of the above product, which was
stirred overnight under nitrogen.
EXAMPLE D
Carbityl O.sup.3 -estradioloxyacetimidate
1. To a solution of 1g of estradiol in 40ml of dry acetone was
added 0.7ml of chloroacetonitrile and 5g of freshly powdered
anhydrous potassium carbonate. The solution was refluxed under
nitrogen overnight, filtered, the solids washed with acetone, and
the combined acetone fractions evaporated. The residue was
dissolved in chloroform, filtered through silica, discarding early
fractions which were product free. The remaining fractions were
evaporated, the residue taken up in ethyl ether and the resulting
crystals isolated. 760mg. m.p. 110.degree.-13.degree..
Recrystallization from ethyl ether yielded a product having a m.p.
112.degree.-114.degree..
2. Into 1ml of carbitol was dissolved 1mg sodium hydride, followed
by the addition of 31mg of the above product under nitrogen. The
mixture was stirred overnight at room temperature.
EXAMPLE E
Methyl O.sup.3 -morphinoxyacetthioimidate
1. O.sup.3 -Cyanomethylmorphine (200mg) was suspended in 2ml of
methyl mercaptan. To the mixture was added 3mg sodium hydride, the
flask sealed and stirred at room temperature for 24 hours. The
mixture was neutralized with 3.5.mu.l acetic acid and concentrated
in vacuo. The residue was taken up in methylene chloride, filtered
through celite and concentrated in vacuo to yield 220mg of a light
brown foam.
EXAMPLE F
O.sup.3 -Isothiocyanatoethylmorphine
1. In 10ml of THF freshly distilled from lithium aluminum hydride
(LAH) was suspended 400mg of LAH under nitrogen. A solution of
400mg of of chloroacetonitrile in 4ml freshly distitlled THF was
added over 5 minutes, followed by refluxing for 1 hour. The mixture
was allowed to cool and 0.6ml water added followed by 0.6ml 10
weight % sodium hydroxide and 2ml of water. After filtering the
mixture, the salts were washed with THF, the THF fractions
combined, dried with magnesium sulphate under nitrogen, filtered
and the filtrate evaporated yielding 380mg of O.sup.3
-aminoethylmorphine.
2. O.sup.3 -Aminoethylmorphine (200 mg) in 10ml chloroform was
added to a solution of thiophosgene (56.mu.l) and potassium
bicarbonate (482mg) in 55ml water and the mixture stirred for two
hours. The phases were separated and the aqueous phase washed twice
wich chloroform (20ml). The combined chloroform phases were dried
by gravity filtration through three thicknesses of chloroform
moistened filter paper. The choloroform solution was evaporated
yielding 200mg.
EXAMPLE G
O.sup.3 -Morphinoxyacetaldehyde
1. To 6.06g dry morphine in 40 ml degassed DMSO was added 850mg of
56 weight % sodium hydride in mineral oil and the mixture stirred
under nitrogen until hydrogen evolution ceased. Bromoacetaldehyde
diethyl acetal (3ml) was then added and the mixture stirred at
60.degree. under nitrogen overnight. The solvent was then removed
at 40.degree., 0.05mm Hg and the residue purified on a 350g silica
gel HF-254 column, using 10% methanolchloroform as a solvent.
Fractions containing the desired product were collected and the
solvent removed yielding 5.35g (67%).
2. Into 80ml of degassed 1N hydrochloric acid was added 5.9g of the
above product and the mixture allowed to stand overnight. The
solution was then brought up to pH 4.7 by addition of 5N sodium
hydroxide and the water removed at 30.degree. at 0.05mm Hg. The
residue was dissolved in hot isopropanol and cooled to precipitate
NaCl and impurities. The solution was filtered, the filtrate
stripped in vacuo and the residue isolated as a glass. The product
could not be crystallized and was isolated as a glass.
EXAMPLE H
5-(N-Phenylbarbital)pentanoic acid
Into a reaction flask was introduced 48ml of dimethylformamide, 4g
of sodio phenobarbital, 3.68g of ethyl 5-bromopentanoate and 0.8g
of potassium iodide, the mixture heated to 40.degree.C and then
stirred at room temperature overnight. After evaporating to dryness
under a high vacuum, the residue was washed with water, followed by
dissolving the residue in methylene chloride. The organic phase was
then extracted with dilute sodium hydroxide, pH 12, and the
alkaline layer acidified with 6N HCl to pH 2. A mixture of starting
material and product precipitated out which was chromatographed
with 1% methanol in chloroform on 75g silica gel.
Of the 1.44g of the product which is obtained from the column,
1.24g was dissolved in a mixture of 25ml tetrahydrofuran, 25ml of
concentrated HCl and 16ml of water, the mixture stirred overnight,
followed by evaporation of the THF. After diluting with saturated
sodium chloride, the mixture was extracted with methylene chloride,
the organic phase isolated and extracted with saturated bicarbonate
solution. After acidifying the aqueous phase to pH 3 with
concentrated HCl, the aqueous phase was extracted with methylene
chloride, washed with water and then evaporated to yield 0.95g. The
0.95g was recrystallized from a mixture of diethyl ether-heptane,
to yield 700mg, m.p. 122.degree.-123.degree. .
EXAMPLE I
4-(5'-Phenylbarbituryl-5')crotonic acid
Into a reaction flask was introduced 100mg (0.49mmole) of
5-phenylbarbituric acid, 24mg (0.5mmole) of sodium hydride and 5ml
of DMF and the mixture stirred vigorously until a clear solution
was obtained. To the mixture was then added 145mg (103.mu.l,
0.75mmole) of ethyl 4-bromocrotonate. After stirring the mixture
overnight at room temperature, the reaction mixture was evaporated
to dryness under high vacuum and the residue partitioned between
ethyl acetate and dilute hydrochloric acid. After extracting the
aqueous layer with ethyl acetate, the organic layers were combined,
and washed twice with water and once with brine, followed by drying
over sodium sulphate. The dried solution was then evaporated to
dryness, and the residue chromatographed employing a 1:1
benzene-ethyl acetate mixture.
The ester (50mg, 0.16mmole) prepared above was dissolved in 1ml of
1N aqueous sodium hydroxide at room temperature. After about 15
minutes, the mixture was acidified with 6N HCl and the precipitate
filtered and dried to give 35mg of a white powder. m.p.
226.degree.-8.degree..
EXAMPLE J
5-(N-Diphenylhydantoinyl)pentanoic acid
To a stirring suspension of 3.4g of sodio diphenylhydantoin in 20ml
of dry DMF was added 2.63g of ethyl 5-bromopentanoate and a trace
of potassium iodide. After stirring the mixture overnight at
60.degree., the solution was diluted with water and extracted with
diethylether. After washing the ethereal solution with water, the
ethereal solution was dried, filtered and the filtrate evaporated
to an oil, which solidified and was recrystallized from aqueous
ethanol. Total yield 3.2g.
The ester prepared above (2.0g) was dissolved in 80ml dioxane and
40ml 10 weight % aqueous potassium hydroxide added. The phases
separated but stirring was vigorously continued for 10 minutes, at
which time additional water was added and a single phase formed.
The aqueous solution was extracted with ether three times,
acidified and filtered to give 1.5g of acid, which was
recrystallized from benzene.
EXAMPLE K
2-(N-Diphenylhydantoinyl)ethoxyacetic acid
Into a reaction flask was introduced 4g of sodio diphenylhydantoin,
3ml of 2-chloroethoxyacetonitrile and 120ml of DMF and the mixture
was stirred under nitrogen at 35.degree. for 15 minutes, followed
by raising the temperature to 60.degree. and continuing the
stirring for an additional 24 hours. After evaporating to dryness,
the residue was taken up in diethylether, and the ethereal solution
washed twice with water, once with 0.05N aqueous sodium hydroxide
and once with aqueous sodium chloride, followed by drying with
magnesium sulphate. The solution was then evaporated, the residue
taken up in 60ml ethanol and the solution heated to boiling to
yield 3.49g of white crystals. After recrystallizing from ethanol,
the product had a m.p. 125.degree.-128.degree..
Into 15ml of ethanolic 1N sodium hydroxide was introduced 200mg of
the above nitrile and the mixture stirred overnight. Water was
added, and the ethanol evaporated to yield a clear solution which
was acidified to pH 1 with 6N HCl. The precipitate was isolated by
filtration to yield 187mg of a white powder. m.p.
160.degree.-168.degree..
EXAMPLE L
2-(N-Diphenylhydantoinyl)propionic acid
Into a reaction flask was introduced 825mg sodio diphenylhydantoin,
543mg of ethyl 2-bromopropionate, and 10ml of DMF, the mixture
heated to 60.degree. under nitrogen and 40mg potassium iodide added
to the stirred solution. After heating overnight, the reaction
mixture was poured into 25ml of water, the flask washed with water
and ether, the liquids combined and extracted twice with a total
volume of 100ml of ether, and the ethereal extracts washed three
times with a total volume of 75ml of water and once with brine.
After evaporating the ether, the solution was flashed with a
mixture of benzene, chloroform and ethanol, followed by flashing
with carbon tetrachloride to yield an oil. The oil was dissolved in
diethyl ether, the ethereal solution washed twice with water (total
volume 25ml), dried over sodium sulphate and evaporated to an oil
which was flashed with carbon tetrachloride, followed by
chloroform, followed by a mixture of benzene and ethanol. The
residue was dissolved in hot ethanol, a portion of the ethanol
evaporated, and water added to cloud point. Upon standing, an oil
formed, which was repeatedly redissolved by repeated reheating and
cooling, followed by addition of ethanol, at which time crystals
formed which quickly became an oil. Benzene-ethanol was added and
the solution evaporated to leave an oil.
Into approximately 12ml of THF and 4ml 1N aqueous sodium hydroxide
was dissolved the oil prepared above. The two phase solution was
stirred at room temperature for about 60 hours. The THF was then
stripped in vacuo, the solution acidified to pH 1 with 6N HCl, at
which time a solid formed which was filtered and dried.
The solid was further purified by dissolving in 50ml diethyl ether,
the ethereal solution washed with 50ml of saturated bicarbonate,
the bicarbonate layer acidified to produce a precipitate which was
isolated, extracted three times with diethyl ether for a total
volume of 100ml and the diethyl ether evaporated to dryness to
yield 673mg. The product could be recrystallized by dissolving in
methanol and adding chloroform to the cloud point.
Because of the high turnover rate for the glucose-6-phosphate
dehydrogenase, as well as the substantial degree of activity which
is retained after conjugation with haptens, highly sensitive assays
can be developed for a wide variety of haptens. Of course, the
sensitivity of any particular enzyme conjugate in an assay is based
on keeping all of the variables constant. Two significant
considerations in an immunoassay are: (1) the lowest concentration
level at which the material can be detected with some degree of
reliability; and (2) the spread between various concentration
levels. In order to evaluate the G-6PDH assay, standards were
prepared having varying concentrations of the drug of interest. The
assay was carried out as follows. Serum (50.mu.l) containing the
drug at the particular concentration was diluted with 250.mu.l of
buffer, Tris-HCl, pH 8.2 in order to insure quantitative transfer
to the cuvette. To the dilute serum was then added 50.mu.l of the
appropriate antibody at a concentration of about 4-5 .times.
10.sup.-.sup.8 M in binding sites (as determined by FRAT
immunoassay, supplied by Syva Company), 0.1M NAD and 0.066M
G--6--P. Quantitative transfer was achieved with 250.mu.l of
buffer. Finally, the appropriate enzyme conjugate was added which
had sufficient enzyme to provide an activity in the absence of
antibody of 200 .DELTA.OD/min at 340 nm in the assay mixture, and
the transfer made quantitative with 250.mu.l of buffer, to provide
a final volume of 0.9ml. The entire mixture was allowed to stand
and equilibrate for one minute and the change in optical density
read for the second minute at 340nm. The following table indicates
the readings for the various standard solutions with different
drugs.
TABLE VI ______________________________________ Morphine
Phenobarbital Diphenylhydantoin conc. reading conc. reading conc.
reading ng/ml .DELTA.OD/min .mu.g/ml OD/min .mu.g/ml OD/min
______________________________________ 0 102 0 140 0 122 1 103 1
151 1 124 5 111 5 163 5 134 10 116 10 170 10 141
______________________________________
It is evident from the above results, that concentrations of a few
ng with morphine or a few .mu.g with phenobarbital and
diphenylhydantoin are readily determinable rapidly from serum. It
is believed, that further improvement in the assays of the latter
two drugs can be achieved with further refinement as to the
antibodies. Therefore, the use of glucose-6-phosphate dehydrogenase
as the enzyme provides an opportunity for extremely selective and
sensitive tests for a wide variety of different drugs having widely
varying structures.
The use of glucose-6-phosphate dehydrogenase has many desirable
characteristics when employed in an homogeneous enzyme immunoassay.
The high turnover rate of the enzyme provides the opportunity for
an extremely sensitive test for determining drugs at very low
concentration. Furthermore, the enzyme can be conjugated so as to
be readily inhibitable, without undesirably high deactivation of
the enzyme. Furthermore, the enzyme is relatively stable so it can
be prepared as a reagent and stored and shipped. In addition, the
enzyme employs a substrate which is colored, having strong
absorption in the far ultraviolet region, and therefore can be
easily detected in a conventional spectrophotometer.
Although the foregoing invention has been described in some detail
by way of illustration and example for purposes of clarity of
understanding, it will be obvious that certain changes and
modifications may be practiced within the scope of the appended
claims.
* * * * *